|Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden|
ZR Chalmers, CF Connelly, D Fabrizio, L Gay, SM Ali, R Ennis, A Schrock, ...
Genome medicine 9 (1), 1-14, 2017
|Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing|
GM Frampton, A Fichtenholtz, GA Otto, K Wang, SR Downing, J He, ...
Nature biotechnology 31 (11), 1023-1031, 2013
|Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial|
RL Coleman, AM Oza, D Lorusso, C Aghajanian, A Oaknin, A Dean, ...
The Lancet 390 (10106), 1949-1961, 2017
|Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial|
EM Swisher, KK Lin, AM Oza, CL Scott, H Giordano, J Sun, GE Konecny, ...
The lancet oncology 18 (1), 75-87, 2017
|Emergence of Constitutively Active Estrogen Receptor-α Mutations in Pretreated Advanced Estrogen Receptor–Positive Breast CancerESR1-Activating Mutations in Advanced Breast Cancer|
R Jeselsohn, R Yelensky, G Buchwalter, G Frampton, F Meric-Bernstam, ...
Clinical cancer research 20 (7), 1757-1767, 2014
|Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 BlockadeHybrid Capture–Based NGS and Response to Anti–PD-1|
DB Johnson, GM Frampton, MJ Rioth, E Yusko, Y Xu, X Guo, RC Ennis, ...
Cancer immunology research 4 (11), 959-967, 2016
|A direct characterization of human mutation based on microsatellites|
JX Sun, A Helgason, G Masson, SS Ebenesersdóttir, H Li, S Mallick, ...
Nature Genetics, 2012
|Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian CarcinomaSecondary Mutations …|
O Kondrashova, M Nguyen, K Shield-Artin, AV Tinker, NNH Teng, ...
Cancer discovery 7 (9), 984-998, 2017
|Non-V600BRAF mutations define a clinically distinct molecular subtype of metastatic colorectal cancer|
JC Jones, LA Renfro, HO Al-Shamsi, AB Schrock, A Rankin, BY Zhang, ...
Journal of Clinical Oncology 35 (23), 2624, 2017
|BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian CarcinomaBRCA Reversion …|
KK Lin, MI Harrell, AM Oza, A Oaknin, I Ray-Coquard, AV Tinker, ...
Cancer discovery 9 (2), 210-219, 2019
|Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated …|
AM Oza, AV Tinker, A Oaknin, R Shapira-Frommer, IA McNeish, ...
Gynecologic oncology 147 (2), 267-275, 2017
|Total mutation burden (TMB) in lung cancer (LC) and relationship with response to PD-1/PD-L1 targeted therapies.|
DR Spigel, AB Schrock, D Fabrizio, GM Frampton, J Sun, J He, K Gowen, ...
Journal of Clinical Oncology, 2016
|Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition|
DA Fabrizio, TJ George Jr, RF Dunne, G Frampton, J Sun, K Gowen, ...
Journal of gastrointestinal oncology 9 (4), 610, 2018
|ALK, ROS1, and NTRK rearrangements in metastatic colorectal cancer|
F Pietrantonio, F Di Nicolantonio, AB Schrock, J Lee, S Tejpar, ...
JNCI: Journal of the National Cancer Institute 109 (12), 2017
|A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal|
JX Sun, Y He, E Sanford, M Montesion, GM Frampton, S Vignot, JC Soria, ...
PLoS computational biology 14 (2), e1005965, 2018
|Comprehensive genomic profiling of 282 pediatric low‐and high‐grade gliomas reveals genomic drivers, tumor mutational burden, and hypermutation signatures|
A Johnson, E Severson, L Gay, JA Vergilio, J Elvin, J Suh, S Daniel, ...
The oncologist 22 (12), 1478-1490, 2017
|Genomic profiling of small-bowel adenocarcinoma|
AB Schrock, CE Devoe, R McWilliams, J Sun, T Aparicio, PJ Stephens, ...
JAMA oncology 3 (11), 1546-1553, 2017
|Relapsed Classic E-Cadherin (CDH1)–Mutated Invasive Lobular Breast Cancer Shows a High Frequency of HER2 (ERBB2) Gene MutationsERBB2 Mutations in Lobular Breast Cancer|
JS Ross, K Wang, CE Sheehan, AB Boguniewicz, G Otto, SR Downing, ...
Clinical cancer research 19 (10), 2668-2676, 2013
|A signal abnormality index for arterial blood pressure waveforms|
JX Sun, AT Reisner, RG Mark
2006 Computers in Cardiology, 13-16, 2006
|Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3|
JS Ross, M Fakih, SM Ali, JA Elvin, AB Schrock, J Suh, JA Vergilio, ...
Cancer 124 (7), 1358-1373, 2018